Clinical Trial Search

Primary: 3-point Major Adverse Cardiovascular Event (MACE) — 0.87; 0.85; 1.19; 0.97 Hazard Ratio

Primary: Changes in Short-interval Intracortical Inhibition (SICI) During the Follicular Phase — 0.78; 0.83; 0.93; 1.03 ratio to the unconditioned stimulus MEP — p=>0.05

Primary: Perceived Stress Scale — 2.79; 2.71; 2.65 units on a scale

Primary: Investigator Conspicuity Score Difference in Ureter Between WL and NIR-F at 30 Minutes [Adult (Normal/Mild): WL/NIR-F] — 2.7; 4.3 score on a scale — p=<0.001

Primary: Change in Perceived Social Support — -5.06; 2.91 units on a scale

Primary: Change in Moderate to Vigorous Physical Activity (MVPA) — 6.1; 7.1; 5.0; 8.2 minutes per day

Primary: Participants With Recurrence Free Survival for Colorectal Cancer Participants With Resected Liver Metastases — 69; 47 percentage of participants

Primary: Rate of Appearance of Acetate — 7.40; 7.69; 9.29; 14.7 umol/kg/min

Primary: Change From Baseline to Week 12 in ESSDAI Score — -5.60; -5.29 score on a scale

Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants

Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on IGA at Week 16. — 65 percentage of participants

Primary: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90 — 36; 31; 37; 35 Participants — p=0.54

Primary: Left Ventricular Ejection Fraction (LVEF) — 61.1; 59.0; 61.9; 58.4 percent

Primary: Mean Binocular Visual Acuity at Distance (4 Meters) at Week 1 — -0.08; -0.08 logMAR

Primary: EIT Metric Global Inhomogeneity Index at 31 Weeks Post Menstrual Age in Those Successful in Discontinuation of Non-invasive Ventilation at 32 Weeks Post Menstrual Age…